Front Page VSPN Message Boards Chat Library Continual Education Search MyVSPN - Coming Soon Help Frequently Asked Questions Send us Feedback! Go to VIN Industry Partners Go to VetQuest Go to Veterinary Partner Go to Y2Spay
 
Menu bar   Go to the VIN.com Portal
 

ABSTRACT OF THE WEEK

Journal of veterinary internal medicine/ American College of Veterinary Internal Medicine
Volume 35 | Issue 3 (May 2021)

The Mitral INsufficiency Echocardiographic score: A severity classification of myxomatous mitral valve disease in dogs.

J Vet Intern Med. May 2021;35(3):1238-1244.
Tommaso Vezzosi1, Giovanni Grosso2, Rosalba Tognetti3, Valentina Meucci4, Valentina Patata5, Federica Marchesotti6, Oriol Domenech7
1 Department of Veterinary Sciences, University of Pisa, Pisa, Italy.; 2 Department of Veterinary Sciences, University of Pisa, Pisa, Italy.; 3 Department of Veterinary Sciences, University of Pisa, Pisa, Italy.; 4 Department of Veterinary Sciences, University of Pisa, Pisa, Italy.; 5 Department of Cardiology, Anicura Istituto Veterinario Novara, Granozzo con Monticello, Italy.; 6 Department of Cardiology, Anicura Istituto Veterinario Novara, Granozzo con Monticello, Italy.; 7 Department of Cardiology, Anicura Istituto Veterinario Novara, Granozzo con Monticello, Italy.
© 2021 The Authors. Journal of Veterinary Internal Medicine published by Wiley Periodicals LLC on behalf of American College of Veterinary Internal Medicine.

Abstract

BACKGROUND:There is no commonly shared severity score for myxomatous mitral valve disease (MMVD) based on routinely acquired echocardiographic variables.
HYPOTHESIS/OBJECTIVES:To propose an easy-to-use echocardiographic classification of severity of MMVD in dogs.
ANIMALS:Five hundred and sixty dogs with MMVD.
METHODS:This was a retrospective, multicenter, observational study. The proposed Mitral INsufficiency Echocardiographic (MINE) score was based on 4 echocardiographic variables: left atrium-to-aorta ratio, left ventricular end-diastolic diameter normalized for body weight, fractional shortening, and E-wave transmitral peak velocity. Specific echocardiographic cutoffs were defined based on previous prognostic studies on MMVD, and severity scores were assigned as follows: mild (score: 4-5), moderate (score: 6-7), severe (score: 8-12), late stage (score: 13-14).
RESULTS:Median survival time was significantly different (P < .05) between the proposed severity classes: mild (2344 days, 95% confidence interval [CI] 1877-2810 days), moderate (1882 days, 95% CI 1341-2434 days), severe (623 days, 95% CI 432-710 days), and late stage (157 days, 95% CI 53-257 days). A MINE score >8 was predictive of cardiac death (area under the curve = 0.85; P < .0001; sensitivity 87%, specificity 73%). In the multivariable analysis, all the echocardiographic variables of the MINE score were independent predictors of death because of heart disease (P < .001).
CONCLUSIONS AND CLINICAL IMPORTANCE:The MINE score is a new easy-to-use echocardiographic classification of severity of MMVD, which has been proven to be clinically effective as it is associated with survival. This classification provides prognostic information and could be useful for an objective echocardiographic assessment of MMVD.

Keywords
cardiac death; heart failure; mitral regurgitation; prognosis; survival;

Article Tools:
   Medline
   Email to me

Archives Highlights:
Pelvic Limb Lameness in a Cat
Although surgical reduction of patellar fractures may seem like a good option, surgical failure was reported in 86% of cats with feline knees and teeth syndrome. Therefore, nonsurgical, conservative approaches should be considered.
Validation of a flash glucose monitoring system in outpatient diabetic cats.
Paired interstitial glucose and automated biochemistry analyzer glucose concentrations (139 samples) had excellent correlation as did interstitial glucose and point-of-care glucometer glucose concentrations (142 samples). Sensor failure or displacement were recorded for 12/15 (80%) sensor placements. Median time of sensor activity was 7 days (range, 2-13 days).
Effect of Clostridium butyricum on Gastrointestinal Infections.
Owing to its preventive and ameliorative effects on gastrointestinal infections, C. butyricum MIYAIRI 588 (CBM 588) has been used as a probiotic in clinical and veterinary medicine for decades. C. butyricum is widely effective against Clostoridioides difficile, the causative pathogen of nosocomial infections; Helicobacter pylori, the causative pathogen of gastric cancer; and antibiotic-resistant Escherichia coli. C. butyricum is expected to be one of the antimicrobial-resistance (AMR) countermeasures for the One-health approach.
Using efficiency models to redefine veterinary practice following Covid-19.
This article illustrates how using efficiency models can help practices recover and redefine their working models following the pandemic.
Clinical Efficacy and Safety of Malarone®, Azithromycin and Artesunate Combination for Treatment of Babesia gibsoni in Naturally Infected Dogs.
The dogs received combined therapy with Malarone (13.5 mg/kg PO q24 h), azithromycin (10 mg/kg PO q24 h), and artesunate (12.5 mg/kg PO q24 h) for 10 days. The combined treatment improved hematology and biochemical parameters to the reference range gradually during the first 14 days, resulting in stable values until day 56 after treatment. No clinically apparent adverse effects were reported during treatment and monitoring. No relapses of parasitemia were detected in control days 180, 360, 540, and 720 in all dogs.

Back Print Save Bookmark in my Browser Email this article to me. Top of Page. VSPN AOW : The Mitral INsufficiency ...
Contact Us